Clinical Trials in Chambray-lès-Tours, France
53 recruiting
Showing 1–20 of 60 trials
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Takeda268 enrolled193 locationsNCT06233461
Recruiting
Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
Incyte Corporation466 enrolled162 locationsNCT07214779
Recruiting
Phase 3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Solid Tumors
Incyte Corporation588 enrolled212 locationsNCT07522073
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled167 locationsNCT06824467
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche425 enrolled173 locationsNCT06819891
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Heart FailureArrhythmiaBradycardia+1 more
Medtronic20,000 enrolled320 locationsNCT00271180
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled199 locationsNCT06588855
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 3
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Carcinoid TumorCarcinoid Tumor of PancreasCarcinoid Tumor of Liver+6 more
Crinetics Pharmaceuticals Inc.141 enrolled51 locationsNCT07087054
Recruiting
PRostate Olaparib Real World Evidence Study
Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled289 locationsNCT07207811
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Acute Coronary Syndrome
Novartis Pharmaceuticals300 enrolled58 locationsNCT07102628
Recruiting
Phase 3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled536 locationsNCT06492616
Recruiting
Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Peripheral Arterial Disease
Eli Lilly and Company1,205 enrolled138 locationsNCT07223593
Recruiting
Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by ECMO-VA for Refractory Cardiogenic Shock
Cardiac Rhythm Disorder
Assistance Publique - Hôpitaux de Paris600 enrolled20 locationsNCT05788120
Recruiting
Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled207 locationsNCT07052903